About Trius Therapeutics
Trius Therapeutics is a Healthcare company based in San Diego (United States) founded in 2004, and was acquired by Cubist Pharmaceuticals in July 2013. Antibiotics for serious infections are discovered, developed, and commercialized. Trius Therapeutics has raised $69.16 million across 4 funding rounds from investors including Kleiner Perkins, Cubist Pharmaceuticals and FinTech Global Incorporated. Trius Therapeutics offers products and services including LLC Formation Guides and Service Reviews. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Trius Therapeutics focuses on the discovery, development, and commercialization of antibiotics for serious infections. It developed tedizolid phosphate that has completed phase 3 clinical trial for the treatment of acute bacterial skin and skin structure infections and completed phase 1 clinical trial for the treatment of pneumonia. The tedizolid phosphate is a novel antibiotic for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus. The company also developed GyrBParE, which are in preclinical program and are targets of the fluoroquinolone class of antibacterial agents, such as ciprofloxacin It was acquired by Cubist Pharmaceuticals in July 2013.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website triusrx.com
- Acquired by Cubist Pharmaceuticals (Jul 2013)
- Total Equity Funding$69.16M (USD)
in 4 rounds
- Latest Funding Round$30.16M (USD), Post-IPO
Jun 2011
- InvestorsKleiner Perkins
& 6 more
- Acquired byCubist Pharmaceuticals
(Jul 2013)
Products & Services of Trius Therapeutics
Trius Therapeutics offers a comprehensive portfolio of products and services, including LLC Formation Guides and Service Reviews.
Provides step-by-step instructions for starting LLCs in US states
Offers evaluations of legal and business formation services
Funding Insights of Trius Therapeutics
Trius Therapeutics has successfully raised a total of $69.16M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30.16 million completed in June 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $69.16M
- Total Rounds 4
- Last Round Post-IPO — $30.16M
- First Round $20M
(Feb 2007)
- Investors Count 6
All 4 funding rounds of Trius Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2011 | $30.16M | Post-IPO | – | – | – |
| Nov 2009 | $19.16M | Series B | – | – | – |
| Mar 2008 | $30M | Series B | – | Kleiner Perkins | |
| Feb 2007 | $20M | Series A | – | Sofinnova Investments |
7 investors in total: 7 institutional.
Investors in Trius Therapeutics
Trius Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Kleiner Perkins, Cubist Pharmaceuticals and FinTech Global Incorporated.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
VC firm investing in the US | prismventure.com | Westwood, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Investment banking advisory services | 1994 | fgi.co.jp | Shinagawa, Japan | |
Pharmaceuticals for acute care bacterial infections are developed and commercialized. | 1993 | cubist.com | Lexington, United States |
Investor details for Trius Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Trius Therapeutics
5 dated milestones of Trius Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Trius Therapeutics is founded.
- Funding First funding round of $20.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $30.2M.
- Exit Acquired by Cubist Pharmaceuticals.
Competitors of Trius Therapeutics
Trius Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. |
Detailed competitors of Trius Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Trius Therapeutics (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Trius Therapeutics
Complete news archive for Trius Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Trius Therapeutics
Trius Therapeutics was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Trius Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Trius Therapeutics is a funded company, having raised a total of $69.16M across 4 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Feb 2007.
Trius Therapeutics focuses on the discovery, development, and commercialization of antibiotics for serious infections. It developed tedizolid phosphate that has completed phase 3 clinical trial for the treatment of acute bacterial skin and skin structure infections and completed phase 1 clinical trial for the treatment of pneumonia. The tedizolid phosphate is a novel antibiotic for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus. The company also developed GyrBParE, which are in preclinical program and are targets of the fluoroquinolone class of antibacterial agents, such as ciprofloxacin It was acquired by Cubist Pharmaceuticals in July 2013.
Trius Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
Trius Therapeutics offers LLC Formation Guides and Service Reviews.
Trius Therapeutics has 7 investors. Key investors include Kleiner Perkins, Cubist Pharmaceuticals, FinTech Global Incorporated, Sofinnova, and InterWest.
Yes. Trius Therapeutics was acquired by Cubist Pharmaceuticals in July 2013.